logo
SPARC shares drop nearly 20% after key drug trial fails

SPARC shares drop nearly 20% after key drug trial fails

Business Upturn04-06-2025
By Aman Shukla Published on June 4, 2025, 11:35 IST
Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044). The drop came following an update from Sun Pharmaceutical Industries Limited, SPARC's collaborator, which revealed that the Phase 2 trials for Vibozilimod failed to meet their primary efficacy endpoints.
The drug, which was being tested for treating moderate-to-severe psoriasis and atopic dermatitis, did not show the required 75% improvement in PASI and EASI scores by Week 16. As a result, no further trials will be conducted, marking a significant setback for both companies' specialty drug pipelines.
Shares of Sun Pharma Advanced Research Company (SPARC) opened at ₹185.00 and touched an intraday low of ₹156.14, reflecting a sharp decline. The stock did not move above its opening price, indicating bearish sentiment. SPARC is currently trading closer to its 52-week low of ₹109.30, far below the 52-week high of ₹258.00. As of 11:34 AM, the shares were trading 17.95% lower at Rs 160.15.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Som Distilleries launches Mahavat whiskey in Delhi
Som Distilleries launches Mahavat whiskey in Delhi

Business Upturn

timean hour ago

  • Business Upturn

Som Distilleries launches Mahavat whiskey in Delhi

By Aman Shukla Published on July 28, 2025, 12:51 IST Som Distilleries and Breweries has recently announced the expansion of its premium whiskey brand, Mahavat , into the vibrant and competitive Delhi market. Following its successful debut in Madhya Pradesh, Mahavat has officially secured all regulatory approvals and supply licenses to begin operations in the National Capital Region. The move marks a significant step forward in Som Distilleries' strategy to strengthen its presence across India. With its entry into Delhi, Mahavat is now set to captivate a wider audience of whiskey lovers in one of India's most dynamic and discerning markets. Over the coming weeks, Mahavat will be available at select bars, lounges, and liquor stores across Delhi. Known for its refined taste, bold character, and authentic Indian craftsmanship, the whiskey offers a premium choice for connoisseurs seeking a unique and elevated drinking experience. Delhi is more than just a new market—it is a gateway to greater brand visibility, consumer engagement, and sustained growth. As Som Distilleries continues to build Mahavat's reach across the country, this launch signifies both momentum and ambition in India's premium spirits industry. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Arvind SmartSpaces shares surge over 4% as Q1 revenue jumps 36% YoY to Rs 102 crore
Arvind SmartSpaces shares surge over 4% as Q1 revenue jumps 36% YoY to Rs 102 crore

Business Upturn

timean hour ago

  • Business Upturn

Arvind SmartSpaces shares surge over 4% as Q1 revenue jumps 36% YoY to Rs 102 crore

By Aman Shukla Published on July 28, 2025, 12:55 IST Shares of Arvind SmartSpaces Ltd witnessed a sharp uptick of over 4% in Monday's trade after the company posted robust Q1 FY26 results, signaling strong operational momentum. The stock opened at ₹620.00 and climbed to an intraday high of ₹663.90, compared to the previous close of ₹624.95. As of 12:53 PM, the shares were trading 3.21% higher at Rs 645.00. The company reported a consolidated net profit of ₹11 crore for the quarter ended June 2025, a significant jump from ₹3 crore in the same period last year. Revenue from operations stood at ₹102 crore, marking a 36% year-on-year rise from ₹75 crore. EBITDA also showed healthy growth, rising to ₹21.6 crore from ₹9.5 crore last year. Margins expanded notably to 21.2% versus 12.7% YoY, reflecting operational efficiency and improved project mix. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion

Medscape

time2 hours ago

  • Medscape

Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion

A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store